-
- TOMITA Akihiro
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
Bibliographic Information
- Other Title
-
- 急性骨髄性白血病に対する分子標的療法の進歩
- キュウセイ コツズイセイ ハッケツビョウ ニ タイスル ブンシ ヒョウテキ リョウホウ ノ シンポ
Search this article
Description
Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 56 (2), 130-138, 2015
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205037353088
-
- NII Article ID
- 130004920715
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 026217178
-
- PubMed
- 25765792
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed